{"pmid":32207377,"title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.","text":["Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2.","Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus.","Emerg Microbes Infect","Nie, Jianhui","Li, Qianqian","Wu, Jiajing","Zhao, Chenyan","Hao, Huan","Liu, Huan","Zhang, Li","Nie, Lingling","Qin, Haiyang","Wang, Meng","Lu, Qiong","Li, Xiaoyu","Sun, Qiyu","Liu, Junkai","Fan, Changfa","Huang, Weijin","Xu, Miao","Wang, Youchun","32207377"],"abstract":["Pseudoviruses are useful virological tools because of their safety and versatility, especially for emerging and re-emerging viruses. Due to its high pathogenicity and infectivity and the lack of effective vaccines and therapeutics, live SARS-CoV-2 has to be handled under biosafety level 3 conditions, which has hindered the development of vaccines and therapeutics. Based on a VSV pseudovirus production system, a pseudovirus-based neutralization assay has been developed for evaluating neutralizing antibodies against SARS-CoV-2 in biosafety level 2 facilities. The key parameters for this assay were optimized, including cell types, cell numbers, virus inoculum. When tested against the SARS-CoV-2 pseudovirus, SARS-CoV-2 convalescent patient sera showed high neutralizing potency, which underscore its potential as therapeutics. The limit of detection for this assay was determined as 22.1 and 43.2 for human and mouse serum samples respectively using a panel of 120 negative samples. The cutoff values were set as 30 and 50 for human and mouse serum samples, respectively. This assay showed relatively low coefficient of variations with 15.9% and 16.2% for the intra- and inter-assay analyses respectively. Taken together, we established a robust pseudovirus-based neutralization assay for SARS-CoV-2 and are glad to share pseudoviruses and related protocols with the developers of vaccines or therapeutics to fight against this lethal virus."],"journal":"Emerg Microbes Infect","authors":["Nie, Jianhui","Li, Qianqian","Wu, Jiajing","Zhao, Chenyan","Hao, Huan","Liu, Huan","Zhang, Li","Nie, Lingling","Qin, Haiyang","Wang, Meng","Lu, Qiong","Li, Xiaoyu","Sun, Qiyu","Liu, Junkai","Fan, Changfa","Huang, Weijin","Xu, Miao","Wang, Youchun"],"date":"2020-03-25T11:00:00Z","year":2020,"_id":"32207377","week":"202013|Mar 23 - Mar 29","doi":"10.1080/22221751.2020.1743767","keywords":["COVID-19","SARS-CoV-2","neutralization assay","neutralizing antibody","pseudovirus"],"source":"PubMed","locations":["pseudovirus"],"topics":["Treatment"],"weight":1,"_version_":1662177578785439744,"score":7.055025,"similar":[{"pmid":32196032,"title":"PRESCIENT: platform for the rapid evaluation of antibody success using integrated microfluidics enabled technology.","text":["PRESCIENT: platform for the rapid evaluation of antibody success using integrated microfluidics enabled technology.","Identifying antibodies (Abs) that neutralize infectious agents is the first step for developing therapeutics, vaccines, and diagnostic tools for these infectious agents. However, current approaches for identifying neutralizing Abs (nAbs) typically rely on dilution-based assays that are costly, inefficient, and only survey a small subset of the entire repertoire. There are also intrinsic biases in many steps of conventional nAb identification processes. More importantly, conventional assays rely on simple Ab-antigen binding assays, which may not result in identifying the most potent nAbs, as the strongest binder may not be the most potent nAb. Droplet microfluidic systems have the capability to overcome such limitations by conducting complex multi-step assays with high reliability, resolution, and throughput in a pico-liter volume water-in-oil emulsion droplet format. Here, we describe the development of PRESCIENT (Platform for the Rapid Evaluation of antibody SucCess using Integrated microfluidics ENabled Technology), a droplet microfluidic system that can enable high-throughput single-cell resolution identification of nAb repertoires elicited in response to viral infection. We demonstrate PRESCIENT's ability to identify Abs that neutralize a model viral agent, Murine coronavirus (murine hepatitis virus), which causes high mortality rates in experimentally infected mice. In-droplet infection of host cells by the virus was first demonstrated, followed by demonstration of in-droplet neutralization by nAbs produced from a single Ab-producing hybridoma cell. Finally, fluorescence intensity analyses of two populations of hybridoma cell lines (nAb-producing and non-nAb-producing hybridoma cell lines) successfully discriminated between the two populations. The presented strategy and platform have the potential to identify and investigate neutralizing activities against a broad range of potential infectious agents for which nAbs have yet to be discovered, significantly advancing the nAb identification process as well as reinvigorating the field of Ab discovery, characterization, and development.","Lab Chip","Wippold, Jose A","Wang, Han","Tingling, Joseph","Leibowitz, Julian L","de Figueiredo, Paul","Han, Arum","32196032"],"abstract":["Identifying antibodies (Abs) that neutralize infectious agents is the first step for developing therapeutics, vaccines, and diagnostic tools for these infectious agents. However, current approaches for identifying neutralizing Abs (nAbs) typically rely on dilution-based assays that are costly, inefficient, and only survey a small subset of the entire repertoire. There are also intrinsic biases in many steps of conventional nAb identification processes. More importantly, conventional assays rely on simple Ab-antigen binding assays, which may not result in identifying the most potent nAbs, as the strongest binder may not be the most potent nAb. Droplet microfluidic systems have the capability to overcome such limitations by conducting complex multi-step assays with high reliability, resolution, and throughput in a pico-liter volume water-in-oil emulsion droplet format. Here, we describe the development of PRESCIENT (Platform for the Rapid Evaluation of antibody SucCess using Integrated microfluidics ENabled Technology), a droplet microfluidic system that can enable high-throughput single-cell resolution identification of nAb repertoires elicited in response to viral infection. We demonstrate PRESCIENT's ability to identify Abs that neutralize a model viral agent, Murine coronavirus (murine hepatitis virus), which causes high mortality rates in experimentally infected mice. In-droplet infection of host cells by the virus was first demonstrated, followed by demonstration of in-droplet neutralization by nAbs produced from a single Ab-producing hybridoma cell. Finally, fluorescence intensity analyses of two populations of hybridoma cell lines (nAb-producing and non-nAb-producing hybridoma cell lines) successfully discriminated between the two populations. The presented strategy and platform have the potential to identify and investigate neutralizing activities against a broad range of potential infectious agents for which nAbs have yet to be discovered, significantly advancing the nAb identification process as well as reinvigorating the field of Ab discovery, characterization, and development."],"journal":"Lab Chip","authors":["Wippold, Jose A","Wang, Han","Tingling, Joseph","Leibowitz, Julian L","de Figueiredo, Paul","Han, Arum"],"date":"2020-03-21T11:00:00Z","year":2020,"_id":"32196032","week":"202012|Mar 16 - Mar 22","doi":"10.1039/c9lc01165j","source":"PubMed","locations":["hybridoma","Murine"],"topics":["Treatment"],"weight":1,"_version_":1661818360796545024,"score":192.26817},{"pmid":32104917,"title":"Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis.","text":["Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis.","The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (SARS-Cov-2) nucleic acid RT-PCR test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay which can detect IgM and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at 8 different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories. This article is protected by copyright. All rights reserved.","J Med Virol","Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng","32104917"],"abstract":["The outbreak of the novel coronavirus disease (COVID-19) quickly spread all over China and to more than 20 other countries. Although the virus (SARS-Cov-2) nucleic acid RT-PCR test has become the standard method for diagnosis of SARS-CoV-2 infection, these real-time PCR test kits have many limitations. In addition, high false negative rates were reported. There is an urgent need for an accurate and rapid test method to quickly identify large number of infected patients and asymptomatic carriers to prevent virus transmission and assure timely treatment of patients. We have developed a rapid and simple point-of-care lateral flow immunoassay which can detect IgM and IgG antibodies simultaneously against SARS-CoV-2 virus in human blood within 15 minutes which can detect patients at different infection stages. With this test kit, we carried out clinical studies to validate its clinical efficacy uses. The clinical detection sensitivity and specificity of this test were measured using blood samples collected from 397 PCR confirmed COVID-19 patients and 128 negative patients at 8 different clinical sites. The overall testing sensitivity was 88.66% and specificity was 90.63%. In addition, we evaluated clinical diagnosis results obtained from different types of venous and fingerstick blood samples. The results indicated great detection consistency among samples from fingerstick blood, serum and plasma of venous blood. The IgM-IgG combined assay has better utility and sensitivity compared with a single IgM or IgG test. It can be used for the rapid screening of SARS-CoV-2 carriers, symptomatic or asymptomatic, in hospitals, clinics, and test laboratories. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Li, Zhengtu","Yi, Yongxiang","Luo, Xiaomei","Xiong, Nian","Liu, Yang","Li, Shaoqiang","Sun, Ruilin","Wang, Yanqun","Hu, Bicheng","Chen, Wei","Zhang, Yongchen","Wang, Jing","Huang, Baofu","Lin, Ye","Yang, Jiasheng","Cai, Wensheng","Wang, Xuefeng","Cheng, Jing","Chen, Zhiqiang","Sun, Kangjun","Pan, Weimin","Zhan, Zhifei","Chen, Liyan","Ye, Feng"],"date":"2020-02-28T11:00:00Z","year":2020,"_id":"32104917","week":"20209|Feb 24 - Mar 01","doi":"10.1002/jmv.25727","keywords":["COVID-19","Lateral flow immunoassay","Point-of-Care Testing","SARS-CoV-2 Virus Infection","fingerstick blood","rapid IgM-IgG Combined test"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647547719681,"score":151.89378},{"pmid":32031583,"title":"Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia.","text":["Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia.","BACKGROUND: A novel coronavirus of zoonotic origin (2019-nCoV) has recently been identified in patients with acute respiratory disease. This virus is genetically similar to SARS coronavirus and bat SARS-like coronaviruses. The outbreak was initially detected in Wuhan, a major city of China, but has subsequently been detected in other provinces of China. Travel-associated cases have also been reported in a few other countries. Outbreaks in health care workers indicate human-to-human transmission. Molecular tests for rapid detection of this virus are urgently needed for early identification of infected patients. METHODS: We developed two 1-step quantitative real-time reverse-transcription PCR assays to detect two different regions (ORF1b and N) of the viral genome. The primer and probe sets were designed to react with this novel coronavirus and its closely related viruses, such as SARS coronavirus. These assays were evaluated using a panel of positive and negative controls. In addition, respiratory specimens from two 2019-nCoV-infected patients were tested. RESULTS: Using RNA extracted from cells infected by SARS coronavirus as a positive control, these assays were shown to have a dynamic range of at least seven orders of magnitude (2x10-4-2000 TCID50/reaction). Using DNA plasmids as positive standards, the detection limits of these assays were found to be below 10 copies per reaction. All negative control samples were negative in the assays. Samples from two 2019-nCoV-infected patients were positive in the tests. CONCLUSIONS: The established assays can achieve a rapid detection of 2019n-CoV in human samples, thereby allowing early identification of patients.","Clin Chem","Chu, Daniel K W","Pan, Yang","Cheng, Samuel M S","Hui, Kenrie P Y","Krishnan, Pavithra","Liu, Yingzhi","Ng, Daisy Y M","Wan, Carrie K C","Yang, Peng","Wang, Quanyi","Peiris, Malik","Poon, Leo L M","32031583"],"abstract":["BACKGROUND: A novel coronavirus of zoonotic origin (2019-nCoV) has recently been identified in patients with acute respiratory disease. This virus is genetically similar to SARS coronavirus and bat SARS-like coronaviruses. The outbreak was initially detected in Wuhan, a major city of China, but has subsequently been detected in other provinces of China. Travel-associated cases have also been reported in a few other countries. Outbreaks in health care workers indicate human-to-human transmission. Molecular tests for rapid detection of this virus are urgently needed for early identification of infected patients. METHODS: We developed two 1-step quantitative real-time reverse-transcription PCR assays to detect two different regions (ORF1b and N) of the viral genome. The primer and probe sets were designed to react with this novel coronavirus and its closely related viruses, such as SARS coronavirus. These assays were evaluated using a panel of positive and negative controls. In addition, respiratory specimens from two 2019-nCoV-infected patients were tested. RESULTS: Using RNA extracted from cells infected by SARS coronavirus as a positive control, these assays were shown to have a dynamic range of at least seven orders of magnitude (2x10-4-2000 TCID50/reaction). Using DNA plasmids as positive standards, the detection limits of these assays were found to be below 10 copies per reaction. All negative control samples were negative in the assays. Samples from two 2019-nCoV-infected patients were positive in the tests. CONCLUSIONS: The established assays can achieve a rapid detection of 2019n-CoV in human samples, thereby allowing early identification of patients."],"journal":"Clin Chem","authors":["Chu, Daniel K W","Pan, Yang","Cheng, Samuel M S","Hui, Kenrie P Y","Krishnan, Pavithra","Liu, Yingzhi","Ng, Daisy Y M","Wan, Carrie K C","Yang, Peng","Wang, Quanyi","Peiris, Malik","Poon, Leo L M"],"date":"2020-02-08T11:00:00Z","year":2020,"_id":"32031583","week":"20206|Feb 03 - Feb 09","doi":"10.1093/clinchem/hvaa029","source":"PubMed","locations":["Pneumonia","Outbreak","Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism"],"weight":1,"_version_":1661359647133532160,"score":139.24216},{"pmid":32155444,"title":"Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.","text":["Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein.","The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination.","Cell","Walls, Alexandra C","Park, Young-Jun","Tortorici, M Alejandra","Wall, Abigail","McGuire, Andrew T","Veesler, David","32155444"],"abstract":["The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000 deaths. Coronavirus spike (S) glycoproteins promote entry into cells and are the main target of antibodies. We show that SARS-CoV-2 S uses ACE2 to enter cells and that the receptor-binding domains of SARS-CoV-2 S and SARS-CoV S bind with similar affinities to human ACE2, correlating with the efficient spread of SARS-CoV-2 among humans. We found that the SARS-CoV-2 S glycoprotein harbors a furin cleavage site at the boundary between the S1/S2 subunits, which is processed during biogenesis and sets this virus apart from SARS-CoV and SARS-related CoVs. We determined cryo-EM structures of the SARS-CoV-2 S ectodomain trimer, providing a blueprint for the design of vaccines and inhibitors of viral entry. Finally, we demonstrate that SARS-CoV S murine polyclonal antibodies potently inhibited SARS-CoV-2 S mediated entry into cells, indicating that cross-neutralizing antibodies targeting conserved S epitopes can be elicited upon vaccination."],"journal":"Cell","authors":["Walls, Alexandra C","Park, Young-Jun","Tortorici, M Alejandra","Wall, Abigail","McGuire, Andrew T","Veesler, David"],"date":"2020-03-11T11:00:00Z","year":2020,"_id":"32155444","week":"202011|Mar 09 - Mar 15","doi":"10.1016/j.cell.2020.02.058","keywords":["SARS-CoV","SARS-CoV-2","antibodies","coronavirus","cryo-EM","neutralizing antibodies","spike glycoprotein","viral receptor"],"source":"PubMed","locations":["CoVs"],"topics":["Mechanism"],"weight":1,"_version_":1661359647836078080,"score":133.81955},{"pmid":32142651,"title":"SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","text":["SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.","The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention.","Cell","Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan","32142651"],"abstract":["The recent emergence of the novel, pathogenic SARS-coronavirus 2 (SARS-CoV-2) in China and its rapid national and international spread pose a global health emergency. Cell entry of coronaviruses depends on binding of the viral spike (S) proteins to cellular receptors and on S protein priming by host cell proteases. Unravelling which cellular factors are used by SARS-CoV-2 for entry might provide insights into viral transmission and reveal therapeutic targets. Here, we demonstrate that SARS-CoV-2 uses the SARS-CoV receptor ACE2 for entry and the serine protease TMPRSS2 for S protein priming. A TMPRSS2 inhibitor approved for clinical use blocked entry and might constitute a treatment option. Finally, we show that the sera from convalescent SARS patients cross-neutralized SARS-2-S-driven entry. Our results reveal important commonalities between SARS-CoV-2 and SARS-CoV infection and identify a potential target for antiviral intervention."],"journal":"Cell","authors":["Hoffmann, Markus","Kleine-Weber, Hannah","Schroeder, Simon","Kruger, Nadine","Herrler, Tanja","Erichsen, Sandra","Schiergens, Tobias S","Herrler, Georg","Wu, Nai-Huei","Nitsche, Andreas","Muller, Marcel A","Drosten, Christian","Pohlmann, Stefan"],"date":"2020-03-07T11:00:00Z","year":2020,"_id":"32142651","week":"202010|Mar 02 - Mar 08","doi":"10.1016/j.cell.2020.02.052","keywords":["ACE2","COVID-19","SARS-CoV-2","TMPRSS2","coronavirus","entry","neutralization","priming","spike"],"source":"PubMed","locations":["China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment"],"weight":1,"_version_":1661359647750094850,"score":131.25638}]}